Citicoline for Focus, Attention & Memory: What the Trials Show
Educational summary — not medical advice. This is small, short-term, industry-funded evidence in specific populations — not a general "focus pill" claim. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
The honest answer
Exactly two PubMed-indexed trials, both Cognizin-funded, in two different non-general-healthy-adult populations. McGlade 2019 (n=75) found improved attention and psychomotor speed in adolescent males at 250–500mg/day for 28 days. Nakazaki 2021 (n=100) found a secondary episodic-memory improvement in older adults with age-associated memory impairment at 500mg/day for 12 weeks. Both are funded by or co-authored with Kyowa Hakko employees — disclose this every time either is cited. A third, widely-marketed "healthy young women" study has no PMID and isn't MEDLINE-indexed.
The two trials, read carefully
This is the entire indexed evidence base for "citicoline helps attention or memory" in a population that isn't already a stroke or dementia patient — and it deserves a careful reading precisely because retail marketing for this ingredient routinely presents it as more established than it is.
| Study | Population & design | Dose & duration | Result |
|---|---|---|---|
| McGlade 2019 PMID 26179181 | RCT, n=75 healthy adolescent males (51 citicoline/24 placebo) | Cognizin® 250mg or 500mg/day, 28 days | Attention significantly ↑ (p=0.02); psychomotor speed significantly ↑ (p=0.03). Higher weight-adjusted dose predicted better accuracy/signal detectability on secondary measures. Single-sex, adolescent population, n=75. |
| Nakazaki 2021 PMID 33978188 | RCT, n=100 (99 completed) adults 50-85 with age-associated memory impairment (AAMI) | Cognizin® 500mg/day, 12 weeks | Secondary episodic-memory outcome (Paired Associate test) significantly ↑ (p=0.0025); composite memory score significantly ↑ (p=0.0052). AAMI population, not a fully "healthy" sample. |
Both trials share the same funding pattern. McGlade 2019's co-authors Miho Kizaki and Eri Nakazaki are Kyowa Hakko Bio Co. employees, and co-author Toshikazu Kamiya is a Kyowa Hakko U.S.A. employee. Nakazaki 2021 was funded by Kyowa Hakko Bio, and authors Eri Nakazaki and Fumiko Watanabe are Kyowa Hakko Bio employees while Danielle Citrolo is a Kyowa Hakko USA employee. Kyowa Hakko is the maker of Cognizin. This does not make the trials invalid — but it means the entire indexed "citicoline helps attention/memory" evidence base for non-disease populations comes from the ingredient's own manufacturer, and that should be disclosed every single time either trial is cited.
The study that doesn't have a PMID
You may have encountered a claim that citicoline improves attention in "healthy adult women," often attributed to "McGlade et al. 2012." This study is widely referenced in industry and marketing summaries, reportedly published in Food and Nutrition Sciences. It does not appear in PubMed under any author, title, or keyword search tried — including a direct search of McGlade's full indexed publication list — because Food and Nutrition Sciences (Scientific Research Publishing) is not a MEDLINE-indexed journal. If you see this study cited with a PMID anywhere, that PMID is fabricated or misattributed. Treat it as an unindexed, non-peer-reviewed-tier claim if mentioned at all — it should never be given the same evidentiary weight as McGlade 2019 or Nakazaki 2021, both of which are real, indexed, peer-reviewed trials.
The Cochrane counterweight on attention specifically
The 2005 Cochrane systematic review (Fioravanti & Yanagi) pooled 14 trials of CDP-choline in elderly patients with chronic cerebral disorders and found "some evidence" of a positive effect on memory and behavior in the short-to-medium term, with stronger evidence on global clinical impression — but it found no evidence of a beneficial effect on attention specifically, and flagged significant heterogeneity in dosing and design across the pooled trials. This is a 2005 review in an elderly, disease-adjacent population, so it doesn't directly contradict McGlade 2019's attention finding in healthy adolescent males — different populations. But it's honest context: even the highest-rigor systematic review available treats "citicoline helps attention" as unestablished in the population it reviewed, at a time when the McGlade/Nakazaki trials hadn't yet been published or weren't part of that review.
If you're taking it for focus or memory
If you want to try citicoline for this specific reason with realistic expectations, the trial-matched dose is 250–500mg/day (see the dosage guide) — not the much higher stroke-trial dose, and not a guarantee based on two small, industry-funded, short-duration trials in narrower populations than "healthy adult." None of this evidence substitutes for sleep, exercise, or other interventions with stronger evidence for attention and memory. And before choosing a product, see whether Cognizin (the trial-tested raw material) or a generic makes sense for you on best citicoline.
Frequently asked questions
What evidence actually supports citicoline for focus and memory?
Two PubMed-indexed trials: McGlade 2019 (adolescent males, attention/psychomotor speed) and Nakazaki 2021 (older adults with AAMI, episodic memory). Both Kyowa Hakko-funded — disclose every citation.
Is there a study on citicoline for healthy young women's attention?
A "McGlade 2012" study is often cited but is not PubMed/MEDLINE-indexed. Treat it as unverifiable if mentioned at all — never cite it with a PMID.
Does citicoline help attention specifically, or just memory?
McGlade 2019 found an attention benefit in adolescent males; the 2005 Cochrane review found no attention benefit in its elderly disease population. Different populations — not directly contradictory, but honest context.
Is Nakazaki 2021 evidence for "healthy adult" memory?
Its population has age-associated memory impairment (AAMI), not a fully healthy sample — always name this distinction.
Related
- Citicoline: what it is & who it's for
- Citicoline dosage guide — cognition dose vs. stroke-trial dose
- Best citicoline — ranked by cost per mg, Cognizin vs. generic
- Does citicoline work — and vs. alpha-GPC
Sources
- McGlade EC, et al. "The Effect of Citicoline Supplementation on Motor Speed and Attention in Adolescent Males." J Atten Disord. 2019 (Epub 2015). PMID: 26179181 (Kyowa Hakko-funded; co-authors are Kyowa Hakko employees).
- Nakazaki E, et al. "Citicoline and Memory Function in Healthy Older Adults." J Nutr. 2021. PMID: 33978188 (Kyowa Hakko Bio-funded; population has age-associated memory impairment).
- Fioravanti M, Yanagi M. "Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly." Cochrane Database Syst Rev. 2005. PMID: 15846601 (no attention benefit found in reviewed population).